Figure 1.

Kisspeptin administration enhances β‐cell function during IVGTT in humans. A, Following an overnight fast, 15 healthy men (age: 25.2 ± 1.1 years; BMI: 22.3 ± 0.5 kg M⁻²) were administered 1 nmol kg⁻¹ hr⁻¹ kisspeptin or rate‐matched vehicle for 225 minutes, in random order. At T = 45 minutes, 0.3 g kg⁻¹ of 20% dextrose was infused intravenously over 2 minutes. Blood sampling was performed regularly (black arrows), with samples for metabolic profiling collected at T = −15 minutes and T = 45 minutes (green stars). B, Mean plasma kisspeptin levels during IVGTT were higher during kisspeptin infusion compared with vehicle administration as expected; **** P < 0.0001 kisspeptin vs. vehicle using GEE. C, Mean serum insulin levels during IVGTT were higher during kisspeptin infusion compared with vehicle administration; ** P = 0.01 kisspeptin vs. vehicle (multi‐level linear regression). D, Mean IVGTT‐DI was higher during kisspeptin administration (red bar) compared with vehicle administration (blue bar); * P < 0.05 kisspeptin vs. vehicle (paired t‐test). E, Mean plasma glucose levels during IVGTT were similar during kisspeptin and vehicle administration; P = 0.64 kisspeptin vs. vehicle (multi‐level linear regression). Data are presented as mean ± SEM; n = 15 per group